Advisory
Strategic Advisory for AI Healthcare Exit
$200M
Valuation
6 months
Advisory Period
7 qualified
Bidders
35%
Premium Achieved
The Challenge
What Our Client Faced
MedAI, a Singapore-based AI healthcare company specializing in diagnostic imaging AI, engaged us to provide pre-exit legal advisory services. The company had developed FDA-cleared (510(k)) and HSA-registered AI diagnostic tools used by hospitals across ASEAN, with $18M ARR growing at 80% year-over-year. The founders wanted to explore a strategic exit, but the company faced several complexities: its AI models were trained on patient imaging data from hospital partners under research collaboration agreements with varying IP ownership terms; the company held three medical device registrations with HSA (Singapore), TGA (Australia), and FDA (US), each with transfer requirements that could take 3-6 months; key algorithms were co-developed with researchers at NUS and the National University Hospital, with IP ownership split under a complex collaboration framework; and the company's revenue model was based on per-diagnosis pricing, creating revenue recognition complexities that needed to be addressed before buyer due diligence.
Our Approach
How We Handled It
We developed a comprehensive six-month exit preparation program. During months one and two, we conducted a deep IP audit that mapped every component of MedAI's AI diagnostic models. We discovered that the NUS collaboration agreement contained an ambiguous IP clause that could be interpreted to give NUS co-ownership of certain core algorithms. We negotiated a clarification agreement with NUS's IP office that confirmed MedAI's exclusive commercial rights while preserving NUS's academic publication rights — a resolution that took three weeks of intensive negotiation but removed a potential deal-breaker. During months two and three, we addressed the regulatory transfer requirements. Medical device registrations in most jurisdictions cannot be simply assigned — they require notification to or approval from the regulatory authority. We pre-filed transfer applications with HSA, TGA, and FDA, and obtained conditional approvals that would be triggered upon a change of control, reducing the post-closing regulatory timeline from 6 months to 6 weeks. During months three and four, we prepared a comprehensive data room and coordinated with the company's financial advisors to run a structured competitive process. We drafted seller-friendly documentation, including a share purchase agreement template, to set the negotiation starting point. During months five and six, we managed the competitive process alongside the financial advisors, evaluating bids from seven qualified bidders, conducting management presentations, and negotiating final terms with the two shortlisted buyers.
The Outcome
Results & Impact
The competitive process generated seven qualified bids, with final valuations ranging from $160M to $200M. The founders selected the highest bidder — a US-based healthcare technology company — at a $200M valuation, representing a 35% premium over the company's most recent internal valuation. The deal was structured as a share acquisition with a $160M upfront payment and a $40M milestone-based earnout tied to FDA clearance of a next-generation diagnostic tool. The NUS IP clarification agreement, pre-filed regulatory transfers, and clean data room collectively reduced the buyer's due diligence period from the typical 8-10 weeks to just 5 weeks. The transaction closed within 12 weeks of signing the letter of intent — well ahead of the industry average for healthcare M&A. All three medical device registrations were successfully transferred within 6 weeks of closing, thanks to our pre-filing strategy.
Key Takeaways
Lessons Learned
- University collaboration IP terms should be clarified well before an exit process begins — ambiguity in these agreements is a common deal risk in deep-tech M&A.
- Pre-filing regulatory transfer applications can dramatically reduce post-closing timelines for medtech and healthtech acquisitions.
- A structured competitive process with seller-friendly documentation maximizes value and reduces buyer negotiating leverage.
- Healthcare AI transactions require specialized due diligence covering clinical validation, regulatory compliance, and patient data governance.
- Earnout structures tied to FDA clearance milestones can bridge valuation gaps in healthcare AI deals.